HomeRGCC Testing in Oklahoma CityOncotrace and Oncocount (RGCC) Testing in Oklahoma City

Oncotrace and Oncocount (RGCC) Testing in Oklahoma City

Written by Venturis Clinic

Oncotrace and Oncocount are blood tests from RGCC, a specialty laboratory in Greece, that look for circulating tumor cells: cancer cells that have broken away from a tumor and travel in the bloodstream. At Venturis Clinic in Oklahoma City, we draw the sample, ship it to the lab, and go through the report with you so you can bring it to your oncology team. Both tests are investigational, are not FDA-approved, do not diagnose cancer, and are not a substitute for your oncologist, imaging or biopsy.

What circulating tumor cells are

Tumors can shed small numbers of cells into the blood. Because those cells are in the blood, a standard blood draw can capture them. Researchers have studied circulating tumor cells for more than two decades as one form of “liquid biopsy.” In a landmark study of metastatic breast cancer, higher circulating tumor cell counts measured with a different, FDA-cleared system were linked to faster disease progression and shorter survival. That research is the foundation of the field, but it does not validate any one laboratory’s test.

Oncocount and Oncotrace: what each reports

  • Oncocount counts circulating tumor cells in a blood sample. It’s mainly used to watch for change over time during or after treatment.
  • Oncotrace counts circulating tumor cells and also profiles markers on them, describing the cells’ characteristics at the time of the draw.

RGCC also offers Onconomics Plus and Onconomics Extracts, which report how circulating tumor cells respond in the lab to chemotherapy agents and natural compounds. Lab results from cells tested outside the body may not predict how a treatment works in your body. We’ll help you understand which test, if any, fits the question you and your oncologist are trying to answer. See our RGCC testing in Oklahoma City page for the full range.

Who asks about these tests

  • People who’ve finished treatment and want more information between scheduled scans
  • People in active treatment who want to discuss trends with their oncologist
  • People exploring integrative care alongside standard oncology care

These tests are most useful when there’s a specific question or trend to follow. They’re not a screening test for people without a cancer diagnosis.

What these tests are, and what they aren’t

What they are What they aren’t
A blood test that looks for circulating tumor cells A diagnosis of cancer, or proof that cancer is absent
One more piece of information to discuss with your oncologist A replacement for your oncologist, imaging or biopsy
A way to look at change over time with repeat testing FDA-approved, or backed by large clinical trials

What the research shows

Most published research on RGCC’s circulating tumor cell methods comes from small studies, many with authors who work for or with RGCC. A 2022 study in BMC Cancer of 36 people with advanced colorectal cancer estimated the overall predictive accuracy of circulating tumor cell chemosensitivity and gene-expression results at 47%, which the authors described as a baseline for future methods to improve on. Preliminary reports in 2025 described using circulating tumor cell results to adjust treatment in pancreatic and colorectal cancer. The field is moving, and the evidence is still early, which is why we present results as information for your care team rather than as a basis for decisions on their own.

How testing works at Venturis

  1. Free call with Dr. Philipose. We talk through your history and whether testing answers a real question for you.
  2. Consultation. We review your records and help choose the panel.
  3. Blood draw in our Oklahoma City office. Draw days are coordinated with shipping so the sample reaches the lab in usable condition.
  4. Lab analysis. Results usually take about three weeks.
  5. Results review. We go through the report with you in plain language and, with your permission, send a copy to your oncology team.

Frequently asked questions

Can Oncotrace tell me whether I have cancer?
No. It doesn’t diagnose cancer or rule it out, and it doesn’t replace standard screening, imaging or biopsy.

Is Oncotrace FDA-approved?
No. RGCC’s tests are not FDA-approved or FDA-cleared.

Will my oncologist use the results?
Some oncologists find the information useful and some don’t. We’ll send a copy of your report at your request, and your oncologist makes your treatment decisions.

Do I need to travel to Mexico or Greece?
No. Samples drawn in Oklahoma City go to the same RGCC laboratory. Read RGCC testing without a trip to Mexico.

Talk with Dr. Philipose

Book a free 15-minute call with Dr. Philipose. Request a call, book online, or call 405-848-7246. Venturis Clinic, 7917 N May Ave, Suite B, Oklahoma City, OK 73120.

Want the background first? Download our free RGCC testing guide, or see integrative cancer support in Oklahoma City.

References

  1. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-791. PMID 15317891. doi:10.1056/NEJMoa040766
  2. Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021;11(4):858-873. PMID 33811121. doi:10.1158/2159-8290.CD-20-1311
  3. Guadagni S, Masedu F, Fiorentini G, et al. Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases. BMC Cancer. 2022;22:660. PMID 35710393. doi:10.1186/s12885-022-09770-3
  4. Drevs J, Malhotra MS, Sahinbas H, et al. Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results. Cancer Treat Res Commun. 2025;44:100956. PMID 40554947. doi:10.1016/j.ctarc.2025.100956
  5. Drevs J, et al. Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer. Anticancer Res. 2025;45(2):491-502. PMID 39890201. doi:10.21873/anticanres.17438

This article is general education, not medical advice, and it is not a substitute for evaluation by a qualified clinician. It does not establish a physician–patient relationship. Individual results vary, and the studies described report group averages rather than what any one person should expect. Treatments discussed may not be FDA-cleared or approved for the conditions mentioned; where that is the case it is stated in the text. Talk to your own physician before starting, stopping or changing any treatment.

RGCC testing is a laboratory service. It does not diagnose or treat any disease and is not a substitute for care from your oncologist or primary physician.